Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

EKF Diagnostics Welcomes NICE Guidelines for Diabetes Prevention

Published: Thursday, August 16, 2012
Last Updated: Thursday, August 16, 2012
Bookmark and Share
Quo-Test and Quo-Lab HbA1c blood analyzers ideal tools to identify high risk patients.

EKF Diagnostics welcomes the recent release of a public health guidance document to prevent the development of type 2 diabetes in high risk individuals.

“Preventing type 2 diabetes: risk identification and interventions for individuals at high risk” sets out recommendations that include the use of glycated haemoglobin (HbA1c) testing to manage the disease, a particular speciality of EKF Diagnostics, a worldwide manufacturer of near patient analyzers.

The guidelines, written by the UK’s National Institute for Health and Clinical Excellence (NICE), and commissioned by the UK Department of Health, gives recommendations to health care providers for developing a two-stage strategy to identify people at high risk of type 2 diabetes (and those with undiagnosed type 2 diabetes).

The strategy consists of a risk assessment, followed, where necessary, by a blood test to confirm whether people have the disease, or are at high risk of developing it.

Those at high risk are to be provided with a programme to help implement healthy lifestyle changes that prevent or delay the onset of the disease.

The report follows the World Health Organization (WHO) recommendations that glycated haemoglobin (HbA1c) can be used as an alternative to standard glucose measures to diagnose type 2 diabetes among non-pregnant adults.

The benefits of HbA1c measurement, compared to fasting glucose testing, include the convenience for patients, since there is no requirement to fast for a 12-hour period prior to testing.

HbA1c measurements can be easily, reliably and rapidly carried out by EKF’s Quo-Test and Quo-Lab near patient analyzers. For example, fast and accurate results are obtained from the analyzer in just four minutes from 4μl of blood from finger prick or venous sample.

The analyzers are also able to produce accurate quantitative results enabling a clear distinction of the level of risk (WHO has determined that HbA1c levels of 48 mmol/mol (6.5%) or above indicate that someone has type 2 diabetes), and a UK expert group has recognized that there is a continuum of risk across a range of subdiabetic HbA1c levels - so that people with an HbA1c below 42 mmol/mol (6.0%) may also be at risk).

EKF Diagnostics CEO Julian Baines supported the NICE release stating “EKF Diagnostics welcomes the release of the NICE guidance, particularly the recognition that HbA1c can be used in identifying adults at risk of diabetes. The Quo-Test and Quo-Lab range of HbA1c analyzers will greatly aid UK health providers in identifying at risk individuals and monitoring disease and treatment status in patients who are diagnosed with diabetes.”

Baines further commented that “The certified accuracy and ease of use of the Quo-Test and Quo-Lab analyzers will allow care providers to rapidly establish preventative treatment programmes for at risk individuals. This rapid intervention reduces overall treatment costs, because in many at risk cases, simple life style changes, to diet or physical activity levels for example, are sufficient to reduce the chances of disease onset.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

EKF Diagnostics’ Growth Drives New Role Creation
Expanding business welcomes new faces to further strengthen IVD expertise and new product development.
Saturday, July 18, 2015
EKF Diagnostics Collaborates with Joslin Diabetes Center
Supporting the ongoing clinical and commercial development of early Diabetic Kidney Disease biomarkers.
Monday, November 17, 2014
Studies Validate EKF Diagnostics’ Early Stage Test for Progressive DKD
Independent scientific evidence confirms novel sTNFR1/2 biomarkers can accurately predict end-stage renal disease, up to 10 years in advance.
Friday, May 23, 2014
New Clinical Diagnostics Distributor Program Enhances EKF Customer Service
EKF Diagnostics appoints Simona Carnielli as new EMEA Distribution Manager.
Thursday, May 08, 2014
EKF Diagnostics Acquires Separation Technology
Acquisition complements EKF’s existing offering in the hemoglobin testing market place.
Thursday, March 27, 2014
PointMan™ Enriches Low-level DNA Mutations from Whole Blood
Ultra-sensitive PointMan™ enables blood sampling instead of tissue biopsies for cancer patient mutation status assessment.
Wednesday, January 22, 2014
Scientific News
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Making Virus Sensors Cheap and Simple
Researchers at The University of Texas at Austin demonstrated the ability to detect single viruses in a solution containing murine cytomegalovirus (MCMV).
Heart Defect Prediction Technology Could Lead to Earlier, More Informed Treatment
Experimental method uses genetics-guided biomechanics, patient-specific stem cells.
Biosensor Detects Molecules Linked to Cancer, Alzheimer's and Parkinson's
Novel biosensor has been proven capable of detecting molecules associated with neurodegenerative diseases and some types of cancer.
Big Data Can Save Lives
The sharing of genetic information from millions of cancer patients around the world could be key to revolutionising cancer prevention and care, according to a leading cancer expert from Queen's University Belfast.
Fast, Simple Test for Colitis
A minimally invasive screening for ulcerative colitis using emerging infrared technology could be a rapid and cost-effective method for detecting disease that eliminates the need for biopsies and intrusive testing of the human body.
Scans Reveal Babies of Mothers with Gestational Diabetes Have More Body Fat
Researchers at Imperial College London have found that the babies born to mothers with gestational diabetes have more body fat at two months of age compared to babies born to healthy mothers.
New Device Could Improve Cancer Detection
UBC researchers develop a microfluidic device to capture circulating tumor cells.
Plasma Biomarkers for Breast Cancer Diagnosis
Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!